Cytospire Therapeutics raises $83M
Cytospire Therapeutics announced a Series A round of $83M on 5 May 2026. The company operates in HealthTech and is based in United Kingdom. It was founded by Natalie Mount, Co-Founder & CEO.
Founder
Natalie Mount
Co-Founder & CEO, Cytospire Therapeutics
Outreach angles
- -Natalie previously led Adaptate Biotherapeutics from inception through a successful acquisition by Takeda Pharmaceuticals in 2022.
- -She was named Woman Entrepreneur of the Year at the Cancer Research Horizons Innovation and Entrepreneurship Awards 2025.
- -The 61 million pound Series A led by 4BIO Capital with Servier Ventures and British Business Bank advances Cytospire's first-in-class T cell engagers into clinical trials.
Signals
Series ADeep TechHealthcareSecond-Time FounderRegulated IndustryHiring
Round details
Company: Cytospire Therapeutics
Domain: cytospire.com
Amount: $83M
Stage: Series A
Industry: HealthTech
Country: United Kingdom
Announced: 5 May 2026
Other HealthTech raises
Recently funded in United Kingdom